Ipamorelin: Clean Growth Hormone Secretion — How It Works and Why It Is the Starting Point

Ipamorelin is a synthetic pentapeptide and selective agonist of the growth hormone secretagogue receptor. Among GH-stimulating peptides, it is notable for what it does not do: it does not meaningfully elevate cortisol, prolactin, or appetite at therapeutic doses.

By UAE Peptide Clinic Research Desk

Ipamorelin is a synthetic pentapeptide and selective agonist of the growth hormone secretagogue receptor (GHS-R) — the ghrelin receptor. Among GH-stimulating peptides, it is notable for what it does not do: it does not meaningfully elevate cortisol, prolactin, or appetite at therapeutic doses. This selectivity profile makes it the most commonly prescribed GH-axis peptide in physician-supervised longevity protocols.

Mechanism of Action

Ipamorelin binds GHS-R in the pituitary and hypothalamus, stimulating GH release through a pathway independent of GHRH signalling. When combined with a GHRH analogue (such as CJC-1295 or Sermorelin), the two compounds create complementary inputs into the same system — GHRH amplifies pulse amplitude, Ipamorelin adds a distinct ghrelin-mediated stimulus. The combined effect exceeds what either compound produces alone.

Clinical Benefits and Applications

The downstream effects of restored GH pulsatility include improved body composition (reduced adiposity, increased lean mass), better sleep architecture, enhanced recovery from physical exertion, improved skin quality, and better energy. Because Ipamorelin does not produce the cortisol or prolactin side effects of earlier GHRPs, it is generally well-tolerated across a wide patient population.

Ipamorelin is one of the most prescribed peptides at our clinic. It is a frequent starting point for patients new to GH-axis therapy. Explore the protocol at /peptides/ipamorelin or take the quiz at /find-my-stack.